How should a sponsor address suspected misconduct or data fabrication?

• A. Initiate an investigation, preserve records, report to authorities if required, and take corrective actions.
• B. Ignore the suspicions until the next audit.
• C. Immediately terminate the trial without investigation.
• D. Notify only the participants.

Answer: (A)

When there’s a suspicion of misconduct or data fabrication in a clinical trial, the sponsor must act to protect participants and the integrity of the data. The proper course is to initiate a formal investigation right away, gathering and securing all relevant records and data to preserve the evidence and maintain an audit trail. This includes protecting source documents, electronic records, and the data flow, so nothing is destroyed or altered during the inquiry.

If the investigation raises or confirms concerns, the sponsor has a duty to report to the appropriate authorities or regulatory bodies as required by law or regulation. This may involve regulatory agencies, ethics committees or IRBs, and other oversight bodies, depending on the jurisdiction and the severity of the issue. Transparency and timely communication with regulators help ensure that proper safeguards are put in place and that participants’ rights and safety are protected.

Alongside investigation and reporting, the sponsor should implement corrective actions to prevent recurrence. This can include retraining staff, revising data handling and monitoring processes, increasing oversight at the site, or other CAPA measures. The goal is to restore data integrity and ensure ongoing participant safety.

Ignoring suspicions, terminating a trial without investigation, or notifying only participants would fail to address the root problem, risks ongoing harm, and violates regulatory responsibilities.